A Localized Materials‐Based Strategy to Non‐Virally Deliver Chondroitinase ABC mRNA Improves Hindlimb Function in a Rat Spinal Cord Injury Model. Issue 19 (25th August 2022)

• Record Type: Journal Article
• Authors: Khalil, Andrew S.; Hellenbrand, Daniel; Reichl, Kaitlyn; Umhoefer, Jennifer; Filipp, Mallory; Choe, Joshua; Hanna, Amgad; Murphy, William L.
• Is Part Of: Advanced healthcare materials. Volume 11:Issue 19(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-25
• Subjects: biomaterials -- messenger RNA delivery -- non‐viral gene therapy -- regenerative medicines -- spinal cord injury; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.202200206
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: Spinal cord injury often results in devastating consequences for those afflicted, with very few therapeutic options. A central element of spinal cord injuries is astrogliosis, which forms a glial scar that inhibits neuronal regeneration post‐injury. Chondroitinase ABC (ChABC) is an enzyme capable of degrading chondroitin sulfate proteoglycan (CSPG), the predominant extracellular matrix component of the glial scar. However, poor protein stability remains a challenge in its therapeutic use. Messenger RNA (mRNA) delivery is an emerging gene therapy technology for in vivo production of difficult‐to‐produce therapeutic proteins. Here, mineral‐coated microparticles as an efficient, non‐viral mRNA delivery vehicles to produce exogenous ChABC in situ within a spinal cord lesion are used. ChABC production reduces the deposition of CSPGs in an in vitro model of astrogliosis, and direct injection of these microparticles within a glial scar forces local overexpression of ChABC and improves recovery of motor function seven weeks post‐injury. Abstract : A nonviral, biomaterials‐based, and single‐dose messenger RNA (mRNA) therapy improves motor function recovery in an injured rat spinal cord after glial scar formation, unlike previous studies requiring repeated enzyme injections or immediate treatment before scar formation. As the materials and the mRNA can be readily redesigned to encode other therapeutic proteins, this approach may have applications in other disease locations.